Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Non-Current Deffered Revenue (2018 - 2022)

Historic Non-Current Deffered Revenue for Revolution Medicines (RVMD) over the last 5 years, with Q3 2022 value amounting to $5.4 million.

  • Revolution Medicines' Non-Current Deffered Revenue fell 4401.74% to $5.4 million in Q3 2022 from the same period last year, while for Sep 2022 it was $5.4 million, marking a year-over-year decrease of 4401.74%. This contributed to the annual value of $6.6 million for FY2021, which is 2249.73% down from last year.
  • Per Revolution Medicines' latest filing, its Non-Current Deffered Revenue stood at $5.4 million for Q3 2022, which was down 4401.74% from $3.8 million recorded in Q2 2022.
  • Over the past 5 years, Revolution Medicines' Non-Current Deffered Revenue peaked at $28.4 million during Q4 2018, and registered a low of $3.8 million during Q2 2022.
  • Its 5-year average for Non-Current Deffered Revenue is $10.2 million, with a median of $8.5 million in 2020.
  • Per our database at Business Quant, Revolution Medicines' Non-Current Deffered Revenue tumbled by 97.21% in 2021 and then crashed by 4965.23% in 2022.
  • Quarter analysis of 5 years shows Revolution Medicines' Non-Current Deffered Revenue stood at $28.4 million in 2018, then tumbled by 48.17% to $14.7 million in 2019, then crashed by 42.41% to $8.5 million in 2020, then fell by 22.5% to $6.6 million in 2021, then fell by 17.57% to $5.4 million in 2022.
  • Its last three reported values are $5.4 million in Q3 2022, $3.8 million for Q2 2022, and $5.7 million during Q1 2022.